Ifetroban is under clinical development by Cumberland Pharmaceuticals and currently in Phase II for Duchenne Muscular Dystrophy. According to GlobalData, Phase II drugs for Duchenne Muscular Dystrophy have a 61% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ifetroban’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ifetroban overview
Ifetroban (Vasculan, Boxaban, Hepatoren,Portaban) is under development for the treatment of hepatorenal syndrome (HRS), portal hypertension, systemic sclerosis, duchenne muscular dystrophy associated with cardiomyopathy and aspirin exacerbated respiratory disease (AERD), a respiratory disease involving chronic asthma and nasal polyps, metastatic solid tumors including triple negative breast cancer, pancreatic cancer, lung cancer, esophageal cancers, stomach cancer, idiopathic pulmonary fibrosis, progressive fibrosing interstitial lung diseases. The drug candidate is administered through oral route and as infusion through intravenous route. IIt acts by targeting thromboxane A2/prostaglandin H2 receptor.
It was under development for the treatment of pacing-induced ischemia, squamous cell carcinoma (SCCA).
Cumberland Pharmaceuticals overview
Cumberland Pharmaceuticals (Cumberland), is a specialty pharmaceutical company that acquires, develops, and commercializes branded prescription products. Its primary target markets are hospital acute care, gastroenterology, and cancer supportive care. The company offers branded prescription products under Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Hepatoren, Boxaban, Vasculan, Portaban, and RediTrex brand names. Cumberland Pharma promotes approved products through its hospital and gastroenterology sales forces in the US. The company is also establishing a network of international partners to commercialize its products in their countries. Cumberland Pharma is headquartered in Nashville, Tennessee, the US.
For a complete picture of Ifetroban’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
